Chipotle trimmed its sales outlook as younger diners have cut back on visits to the fast-casual restaurant chain.

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

Walmart will offer in‑store pickup of Eli Lilly’s discounted weight‑loss drug Zepbound, giving self‑pay customers easier, ...

CEO David Ricks wants Eli Lilly’s upcoming obesity pill to be accessible to patients who need it, but the company still needs ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and spawning a ...

The collaboration marks the first time patients using LillyDirect, Lilly’s direct-to-consumer healthcare platform can access self-pay pricing for Zepbound vials at a retail pharmacy location.

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

Lilly shares are up about 5% this year. Compared with its peers, the drugmaker has been more insulated from drug price ...

Eli Lilly beat Q3 estimates with $7.02 EPS and $17.60 billion revenue, raising full-year guidance as Zepbound and Mounjaro ...

Eli Lilly stock (NYSE: LLY) is up 7% in a month, warranting investor attention following a key corporate development. Eli ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...